There is currently an open class action lawsuit related to patients harmed by an Alzheimer’s drug called Kisunla (donanemab), which was discontinued in Europe due to serious safety concerns. Kisunla, developed by Eli Lilly, is a monoclonal antibody aimed at reducing amyloid beta plaques in the brain, a hallmark of Alzheimer’s disease. However, it has been linked to dangerous side effects such as brain bleeding, swelling, and a condition known as amyloid-related imaging abnormalities (ARIA). These complications have led to severe neurological damage and even deaths in some patients. The European Medicines Agency refused to authorize Kisunla because the modest benefits did not outweigh these significant risks. Patients who took Kisunla and suffered brain injuries or other serious complications may be eligible to join a class action lawsuit seeking compensation for harm caused by the drug.
The lawsuit centers on allegations that patients were not adequately warned about the risks of brain bleeding and swelling associated with Kisunla. Clinical data showed that ARIA occurred in over a third of patients taking the drug, with serious events in a smaller but significant percentage, including fatalities. This has raised concerns about the drug’s safety profile and the adequacy of the information provided to patients and healthcare providers before its use. The legal action aims to hold the manufacturer accountable for these harms and to provide financial redress to affected patients and their families.
This situation is part of a broader context where Alzheimer’s drugs, which are often urgently needed by patients and families, face intense scrutiny over safety and efficacy. The discontinuation of Kisunla in Europe contrasts with its approval in other countries such as the US, Japan, China, and the UK, highlighting differing regulatory assessments of risk versus benefit. The lawsuit reflects growing attention to the balance between offering new treatments for devastating diseases and ensuring those treatments do not cause unacceptable harm.
While Kisunla is the most prominent example currently involved in litigation, there is no widespread class action lawsuit reported for other discontinued Alzheimer’s drugs at this time. However, given the complexity and risks associated with Alzheimer’s treatments, legal actions may emerge if other drugs are found to cause harm or if patients feel inadequately informed about risks.
In summary, the open class action lawsuit for patients harmed by discontinued Alzheimer’s drugs specifically involves Kisunla, focusing on serious brain injuries linked to the drug’s side effects. Patients affected by these complications are encouraged to seek legal advice to understand their rights and potential eligibility for compensation.
